At 10.6% CAGR, Antidiabetics Market Witness of Emerging Growth by Boehringer Ingelheim, Eli Lilly, Merck, Novo Nordisk and Sanofi


The qualitative research study conducted by Market Study Report titled “Global Antidiabetics Market size Report” provides primary Data, surveys, Scope of the Product and vendor briefings. The Market size dynamic forces have been determined after conducting a detailed study of the Global Antidiabetics Market size.

Antidiabetics Market will reach over USD 110 billion by 2024; as per a new research report.

Growing incidence coupled with increasing risk of diabetes will augment antidiabetics market growth over the coming years. Excess weight significantly escalates risk of type 2 diabetes mellitus (T2DM). Also, the risk of developing diabetes by 25 years of age increases four times in obese children. Thus, rising incidence of diabetes will result into substantial rise in demand for antidiabetics, thereby impelling antidiabetics business growth.

Request a sample of this premium report titled at www.marketstudyreport.com/request-a-sample/467744/?utm_so…

Germany antidiabetics industry accounted for largest revenue size of USD 4,461.7 million of Europe antidiabetics industry in 2017. According to WHO, in 2016, it was estimated that 22.7% people in Germany are suffering from obesity which is the major risk factor associated with diabetes. Mortality rate due to diabetes is also increasing at fast pace. Moreover, availability of medicines, technologies and facilities for the disease treatment will stimulate German antidiabetics market growth.

Some of the major market players involved in global antidiabetics market are Boehringer Ingelheim, Eli Lilly, Merck, Novo Nordisk, and Sanofi. Companies are focusing on partnerships and novel product launch to expand their market presence and enhance customer portfolio.

With accelerating growth in number of diabetes cases, prominent players are concentrating their efforts on developing newer and improved antidiabetic drugs. Many leading players including Sanofi, Novo Nordisk and Eli Lilly have a broad pipeline portfolio of antidiabetic drugs that aim to diversify the set of therapeutic alternatives for diabetes patients. Thus, growing R&D activities should positively impact antidiabetics industry growth in forthcoming timeframe.

Insulin product segment is estimated to witness 12.3% CAGR during the forecast period. High revenue share is attributable to widening use of insulin therapy for the treatment of type 2 diabetes. Besides, insulin is available in several forms depending upon its rate of action. In addition, insulin therapy decreases microvascular complications that should boost adoption rate of insulin in the upcoming years.

Geriatric patient population segment accounted for nearly 42.2% market share in 2017 and is estimated to follow similar trend during the forecast timeline. T2DM is an emerging problem in elderly population. As per American Diabetes Association, about 25% of Americans aged above 60 years of age suffer from diabetes. The risk in treating diabetes through changes in dietary habits is further elevated due to impaired physical functioning. Such factors coupled with rising awareness to educate older population about reducing risk of diabetes will act as high impacting factor for geriatric segment growth.

Oral route of administration segment accounted for 72.6% market share in 2017 and will grow at a significant pace during the forecast timeframe due to effectivity and efficacy of treatment coupled with convenience. A study conducted by International Journal of Pharmaceutical Research indicated that oral antidiabetics are most frequently prescribed hypoglycemics. Above factors will highly contribute to segmental growth in projected period.

Request a discount on standard prices of this premium report titled at www.marketstudyreport.com/check-for-discount/467744/?utm_…

India antidiabetics market is estimated to progress at 14.3% CAGR during the forecast timeframe. Growing adoption of binge eating habits as well as accelerating elderly population will considerably contribute to increase in Indian antidiabetics market. Additionally, firms are undertaking organic growth initiatives to expand in Indian market. For instance, Lupin and Boehringer Ingelheim collaborated for co-marketing its oral antidiabetics across India, that should offer lucrative market growth potential in forthcoming years.

Report Content

Chapter 1. Methodology

1.1. Methodology

1.2. Market definitions

1.3. Forecast parameters

1.4. Data sources

1.4.1. Secondary

1.4.1.1. Paid sources

1.4.1.2. Unpaid sources

1.4.2. Primary

Chapter 2. Executive Summary

2.1. Antidiabetics industry 360 degree synopsis, 2013 – 2024 (USD Million)

2.1.1. Business trends

2.1.2. Product trends

2.1.3. Patient population trends

2.1.4. Route of administration trends

2.1.5. Regional trends

Chapter 3. Antidiabetics Industry Insights

3.1. Industry segmentation

3.2. Industry landscape, 2013 – 2024

3.3. Industry impact forces

3.3.1. Growth drivers

3.3.1.1. Strong product pipeline of antidiabetics

3.3.1.2. Globally rising prevalence of diabetes

3.3.1.3. Increasing prevalence of lifestyle induced disorders such as obesity

3.3.2. Industry pitfalls and challenges

3.3.2.1. Prohibitive cost of insulin

3.4. Regulatory landscape

3.4.1. U.S.

3.4.2. Europe

3.5. Clinical workflow analysis

3.6. Reimbursement scenario

3.6.1. U.S.

3.6.2. Europe

3.6.3. Australia

3.7. Growth potential analysis

3.7.1. By product

3.7.2. By patient population

3.7.3. By route of administration

3.8. Porter’s analysis

3.9. Competitive landscape

3.9.1. Company market share analysis, 2017

3.9.2. Strategy dashboard

3.10. PESTEL analysis

3.11. Pipeline overview, 2018

Chapter 4. Antidiabetics Market, By Product

4.1. Key segment trends

4.2. Insulin

4.2.1. Market size, by region, 2013-2024 (USD Million)

4.2.2. Rapid acting analog

4.2.2.1. Market size, by region, 2013-2024 (USD Million)

4.2.3. Long acting analog

4.2.3.1. Market size, by region, 2013-2024 (USD Million)

4.2.4. Premixed analog

4.2.4.1. Market size, by region, 2013-2024 (USD Million)

4.2.5. Premixed insulin

4.2.5.1. Market size, by region, 2013-2024 (USD Million)

4.2.6. Short acting analog

4.2.6.1. Market size, by region, 2013-2024 (USD Million)

4.2.7. Intermediate acting insulin

4.2.7.1. Market size, by region, 2013-2024 (USD Million)

4.3. Drug class

4.3.1. Market size, by region, 2013-2024 (USD Million)

4.3.2. Alpha glucosidase inhibitors

4.3.2.1. Market size, by region, 2013-2024 (USD Million)

4.3.3. Biguanides

4.3.3.1. Market size, by region, 2013-2024 (USD Million)

4.3.4. Sulphonylureas

4.3.4.1. Market size, by region, 2013-2024 (USD Million)

4.3.5. GLP-1 (Glucagon like peptide) agonists

4.3.5.1. Market size, by region, 2013-2024 (USD Million)

4.3.6. DPP-IV (Dipeptidyl Peptidase) inhibitors

4.3.6.1. Market size, by region, 2013-2024 (USD Million)

4.3.7. Meglitinides

4.3.7.1. Market size, by region, 2013-2024 (USD Million)

4.3.8. SGLT-II (Sodium Glucose Transport Proteins) inhibitors

4.3.8.1. Market size, by region, 2013-2024 (USD Million)

4.3.9. Thiazolidinedione

4.3.9.1. Market size, by region, 2013-2024 (USD Million)

Chapter 5. Antidiabetics Market, By Patient Population

5.1. Key segment trends

5.2. Pediatric

5.2.1. Market size, by region, 2013-2024 (USD Million)

5.3. Adult

5.3.1. Market size, by region, 2013-2024 (USD Million)

5.4. Geriatric

5.4.1. Market size, by region, 2013-2024 (USD Million)

Chapter 6. Antidiabetics Market, By Route of Administration

6.1. Key segment trends

6.2. Insulin syringe/ Insulin pen

6.2.1. Market size, by region, 2013-2024 (USD Million)

6.3. Insulin pump

6.3.1. Market size, by region, 2013-2024 (USD Million)

6.4. Intravenous infusion

6.4.1. Market size, by region, 2013-2024 (USD Million)

6.5. Oral

6.5.1. Market size, by region, 2013-2024 (USD Million)

6.6. Others

6.6.1. Market size, by region, 2013-2024 (USD Million)

Complete report titled at www.marketstudyreport.com/reports/antidiabetics-market/?u…

About Us:

Marketstudyreport.com allows you to manage and control all corporate research purchases to consolidate billing and vendor management. You can eliminate duplicate purchases and customize your content and license management.

Contact Us:

Market Study Report

4 North Main Street,

Selbyville, Delaware 19975

USA

Phone: 1-302-273-0910

US Toll Free: 1-866-764-2150

Email: [email protected]

Website: www.marketstudyreport.com

Blog: www.marketstudyreport.com/blog

This release was published on openPR.



Source link Diabetes Definition

Leave a Reply

Your email address will not be published.


*


Shares